In 2007, the first targeted therapy for HCC—Nexavar (sorafenib)—was approved by the Food and Drug Administration (FDA). It took a decade for the next targeted drug, Stivarga (regorafenib), and the first immunotherapy, Opdivo (nivolumab), to be approved.
